Experimental drug zervimesine made available to patients with lewy body dementia

NCT ID NCT06961760

NO_LONGER_AVAILABLE Disease control Sponsor: Cognition Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers the experimental drug zervimesine (CT1812) to people aged 50 to 86 with mild-to-moderate dementia with Lewy bodies. Participants take one 100 mg pill daily for up to a year. The goal is to provide access to the drug and collect long-term safety information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zervimesine (CT1812)
What this could lead to: If this program shows that zervimesine is safe and well-tolerated over a year, it could support further research into a treatment for dementia with Lewy bodies.
What could go wrong: This is an expanded access program, not a formal trial, so it provides limited evidence of effectiveness. The drug is still experimental, and long-term risks are not fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dementia Lewy body dementia Lewy Body Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIA WITH LEWY BODIES

Contacts and locations

Locations

Banner Sun Health Research Institute

Sun City, Arizona, 85351, United States
Columbia University Medical Center

New York, New York, 10032, United States
Mayo Clinic - Rochester

Rochester, Minnesota, 55905, United States
Ohio State University Wexner Medical Center (OSUWMC)

Columbus, Ohio, 43210, United States
Stanford Neuroscience Heath Center

Palo Alto, California, 94304, United States
Summit Headlands LLC

Portland, Oregon, 97210, United States
University of Colorado Denver - Anschutz Medical Campus

Aurora, Colorado, 80045, United States
University of Miami - Department of Neurology

Boca Raton, Florida, 33433, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.